Their model incorporated a decrease in MRI BC size of less than 50%, ultrasound-measured post-NAT LN cortex greater than 3.5 mm, initial nodal clinical stage N2-N3, negative HER2 status, positive ER status, and a low Ki-67 index, achieving AUCs of 0.84 in the training set and 0.78 in the validation set. This evidence concerns the gene ERBB2 and breast cancer.